Скачать или смотреть A Treatment Approach for Dry Eye Disease with Inflammation | Xiidra Case Study

Full Prescribing Information: https://www.xiidra-ecp.com/globalasse... Patient Information: https://pi.bausch.com/globalassets/pd...

This video explores a treatment approach for patients with dry eye disease (DED) and underlying inflammation. Through a detailed clinical case study of a 55-year-old cab driver, 2 eye care professionals discuss the importance of identifying ocular surface inflammation and how clinical findings can guide the selection of an appropriate treatment choice like Xiidra. This video offers valuable perspectives on managing DED with inflammation.


Key Questions Covered in the Video:

What are the key indicators of inflammation in a patient presenting with dry eye disease?

How can you identify inflammation as a driver of your patients’ dry eye symptoms?

What role do clinical findings, including osmolarity and MMP-9, play in DED?
Why was Xiidra chosen as an initial treatment regimen for this particular patient?


Chapters:
0.00 Introduction, Indication and Important Safety Information
0.28 Case Profile: Patient Background & Symptoms
1.19 Review of Key Clinical Findings
1.56 Treatment Rationale & Plan for DED with Inflammation

2.33 Indication and Important Safety Information

For more on Xiidra, visit us at https://www.xiidra-ecp.com/

Patient Information: https://www.xiidra.com/

Subscribe to our channel:    / @xiidrahcp  


Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).


Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088


For additional safety information, click the links above for Full Prescribing Information and Patient Information.